Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

被引：6
|
作者：
Apolo, Andrea B. [1 ]
Girardi, da Motta Daniel [1 ]
Niglio, Scot Anthony [1 ]
Nadal, Rosa Maria [2 ]
Cordes, Lisa M. [2 ]
Steinberg, Seth M. [3 ]
Costello, Rene
Trepel, Jane B. [4 ]
Lee, Sunmin
Lee, Min-Jung [5 ]
Cao Liang [6 ]
Gulley, James L. [1 ]
Bottaro, Donald P. [7 ]
Saraiya, Biren [8 ,9 ]
Pal, Sumanta K. [10 ]
Quinn, David, I [11 ]
Lara, Primo Lucky N. [12 ]
Parnes, Howard L. [1 ]
Dahut, William L. [13 ]
Mortazavi, Amir [14 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NIH, Bldg 10, Bethesda, MD 20892 USA
[3] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
[4] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[5] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[6] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[7] Ctr Canc Res, Div Canc Treatment & Diag, Bethesda, MD USA
[8] Rutgers Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[9] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[10] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[11] USC Norris Canc Hosp, Los Angeles, CA USA
[12] Univ Calif, Sacramento, CA USA
[13] NCI, Bethesda, MD 20892 USA
[14] Ohio State Univ, Wexner Med Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页数：4
相关论文
共 50 条
  • [11] A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
    Apolo, A. B.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Francis, D. C.
    Cordes, L. M.
    Berniger, M.
    Steinberg, S. M.
    Monk, P.
    Lancaster, T.
    Mayer, T.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [12] Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /-Ipi)
    Lin, Jeffrey
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Nadal, Rosa Maria
    Francis, Deneise C.
    Berniger, Marilise Anne
    Monk, Paul
    Kempf, Jeffrey
    Becker, Murray
    Sokol, Levi
    McKinney, Yolanda
    Knopp, Michael V.
    Wright, Chadwick
    Jung, Alex
    Choyke, Peter L.
    Mena, Esther
    Lindenberg, Liza
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [13] Final results of a phase I "RadVax" trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors.
    Lukens, John Nicholas
    Mick, Rosemarie
    Huang, Alexander Chan Chi
    Han, Nicholas
    Farwell, Michael
    Mitchell, Tara C.
    Amaravadi, Ravi K.
    Schuchter, Lynn Mara
    Berman, Abigail T.
    O'Hara, Mark H.
    Maity, Alisha
    Miller, David
    Minn, Andy
    Vonderheide, Robert H.
    Wherry, E. John
    Maity, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [14] A multicenter phase II study of nivolumab plus /- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
    Chen, James Lin
    Mahoney, Michelle R.
    George, Suzanne
    Antonescu, Cristina R.
    Liebner, David A.
    Van Tine, Brian Andrew
    Milhem, Mohammed M.
    Tap, William D.
    Streicher, Howard
    Schwartz, Gary K.
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [15] Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio
    Vlahovic, Gordana
    Lim, Michael
    Sahebjam, Solmaz
    Baehring, Joachim
    Cloughesy, Timothy
    Voloschin, Alfredo
    Ramkissoon, Shakti H.
    Ligon, Keith L.
    Latek, Robert
    Zwirtes, Ricardo
    Strauss, Lewis
    Paliwal, Prashni
    Harbison, Christopher T.
    Reardon, David A.
    Sampson, John H.
    NEURO-ONCOLOGY, 2018, 20 (05) : 674 - 686
  • [16] Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
    Girardi, Daniel da Motta
    Niglio, Scot Anthony
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] Final Results of a Phase I "RadVax" Trial of Hypofractionated Radiation Combined With Pembrolizumab in Patients With Metastatic Solid Tumors
    Lukens, J. N.
    Mick, R.
    Huang, A. C.
    Han, N.
    Farwell, M. D.
    Mitchell, T. C.
    Amaravadi, R.
    Schuchter, L. M.
    Berman, A. T.
    O'Hara, M.
    Maity, A.
    Miller, D.
    Minn, A. J., III
    Vonderheide, R. H.
    Wherry, E. J.
    Maity, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S67 - S68
  • [18] Updated results from a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Rini, Brian I.
    Mcdermott, David F.
    Lewis, Lionel D.
    Voss, Martin H.
    Sharma, Padmanee
    Pal, Sumanta K.
    Razak, Albiruni
    Kollmannsberger, Christian
    Heng, Daniel Y. C.
    Spratlin, Jennifer
    Mchenry, M. Brent
    Gagnier, Paul
    Amin, Asim
    BJU INTERNATIONAL, 2016, 118 : 20 - 21
  • [19] Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
    Rosenberg, J. E.
    Sharma, P.
    de Braud, F. G. M.
    Basso, U.
    Calvo, E.
    Bono, P.
    Morse, M.
    Ascierto, P. A.
    Lopez-Martin, J. A.
    Brossart, P.
    Rohrberg, K. S.
    Reguart, N.
    Lin, W. H.
    Meadows-Shropshire, S.
    Saci, A.
    Callahan, M.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2018, 29
  • [20] Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
    Zimmer, Lisa
    Livingstone, Elisabeth
    Hassel, Jessica C.
    Fluck, Michael
    Eigentler, Thomas
    Loquai, Carmen
    Haferkamp, Sebastian
    Gutzmer, Ralf
    Meier, Friedegund
    Mohr, Peter
    Hauschild, Axel
    Schilling, Bastian
    Menzer, Christian
    Kieker, Felix
    Dippel, Edgar
    Rosch, Alexander
    Simon, Jan-Christoph
    Conrad, Beate
    Korner, Silvia
    Windemuth-Kieselbach, Christine
    Schwarz, Leonora
    Garbe, Claus
    Becker, Juergen C.
    Schadendorf, Dirk
    LANCET, 2022, 400 (10358): : 1117 - 1129
12345